Systemic hematologic status following intraventricular recombinant tissue-type plasminogen activator for intraventricular hemorrhage: the CLEAR IVH Study Group.

ABSTRACT:

Background and purpose

This is the first prospective evaluation of changes in systemic hematologic status following administration of intraventricular recombinant tissue-type plasminogen activator in patients with intraventricular hemorrhage (IVH).

Methods

Laboratory data from subjects enrolled onto the Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) Trials were analyzed. We analyzed pre- and post- recombinant tissue-type plasminogen activator dosing coagulation parameters. Longer-term changes in hematologic status were studied in subjects who received the study agent after blood clot in the third/fourth ventricles had resolved radiologically.

Results

Plasma fibrinogen increased significantly in both treatment groups. Dosing did not have a significant

SUBMITTER: Herrick DB 

PROVIDER: S-EPMC3233723 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature